Boron neutron capture therapy using mixed neutron beam in patients with malignant glioma
|
Accession number;04A0165431
|
| Title;Boron neutron capture therapy using mixed neutron beam in patients with malignant glioma |
| Author;
KAGEJI TERUYOSHI
(Univ. of Tokushima, Sch. of Med.)
MIZOBUCHI YOSHIFUMI
(Univ. of Tokushima, Sch. of Med.)
NAGAHIRO SHINJI
(Univ. of Tokushima, Sch. of Med.)
NAKAGAWA YOSHINOBU
(Kagawashonibyoin Noshinkeigeka)
|
Journal Title;Shikoku Acta Medica
|
Journal Code:G0586A
|
ISSN:0037-3699
|
|
VOL.59;NO.6;PAGE.292-298(2003)
|
| Figure&Table&Reference;FIG.4, REF.7 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The purpose of this study was to clarify the clinical interim results of boron neutron capture therapy (BNCT) using mixed epithermal-and thermal neutron beams in patients with malignant glioma. The mixed neutron beam for BNCT has been used clinically since 1998. Its great advantage consists of its greater ability than the pure thermal neutron beam to reach sites deep from the brain surface. Sixteen patients with malignant glioma (glioblastoma n=14, anaplastic ependymoma n=1, PNET n=1) underwent mixed epithermal-and thermal neutron beam treatment between 1998 and 2003. They included 2 children younger than 3 years. Sodium borocaptate (Na2B12H11SH, BSH; 80-100 mg/kg) was administered intravenously at 12-15 hr before neutron irradiation. The radiation dose (i.e. physical dose of boron n-alpha reaction) in the he protocol used between 1997 and 2000 (Protocol A) prescribed a maximum tumor volume dose of 15 Gy. In 2001, a new dose-escalated protocol was introduced (Protocol B); it prescribes a minimum tumor volume dose of 18 Gy or, alternatively, a minimum target volume dose of 15 Gy. In both protocols, the maximum vascular radiation dose to the brain surface is not to exceed 15 Gy. Of the 12 patients, 8 were treated according to Protocols A and 4 according to Protocol B. Since 2002, the radiation dose was reduced to 80-90% dose of Protocol B because of acute radiation injury. A new Protocol was applied to four glioblastoma patients (Protocol C). Of the 8 patients treated under Protocol A, 7 died (dissemination n=4, local recurrence, infection, unknown causes, n=1 each). Of the 4 patients treated under Protocol B, 2 died. Concerning the adverse effects of BNCT, Protocol B resulted in higher complication rates with respect to both acute and delayed radiation injury. The estimated median survival time after diagnosis and after BNCT in all patients were 16.7 and 14.6 months, respectively.... (author abst.) |
|
|
|
Related Articles;
|
|
